Adlai Nortye stock
ANLNASDAQAdlai Nortye Ltd., HealthcareISIN US00704R1095
36Score 36 out of 100, Weak
Price and trend
61 / 100
Price history
+553% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 10% below it.
Since January 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 37% below its 52-week high. Largest decline in 3 years: 94% (September 2023 to December 2025).
Chart figures for advanced users
- SMA 50$13.11
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.73
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$0.88
- The lowest closing price of the last twelve months.
- Resistance$16.60
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Adlai Nortye Ltd. belongs to the Biotechnology industry (Singapore) and, with a market value of $558.4M, is number 234 of 296 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- MEQIRI Score 36 out of 100 (Weak): rank 611 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Volatile share priceVolatility 154% a year over the last 12 months.Stability 53
- DilutionShare count up 26% since 2020.Capital allocation 21
- Loss-makingLoss of $35.53M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 34 to 36.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −714%, net −711%. Last 12 months: net −100%. From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 14 Aug 2026above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −0.18+0.4%
- Revenue
- $17.2M0.0%
- Earnings per share
- −0.29−0.2%
- Revenue
- $7.64M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $411,191 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Shares and prices per ordinary share as filed with the SEC, not per depositary receipt.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Adlai Nortye
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Capricor TherapeuticsCAPR $649.77M32
- Monopar TherapeuticsMNPR $612.75M42
- GenfitGNFT.PA $609.09M44
- Helus PharmaHELP $582.03M40
- ValnevaVLA.PA $567.35M31
- Entera BioENTX $560.72M44
- REGENXBIORGNX $560.06M32
- Crescent BiopharmaCBIO $548.24M33
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 25 Oct 2024)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.